B.R.A.I.N. Biotechnology Research and Information Network (BNN) AI Stock Analysis

• Market Cap: €45.01M
• Dividend Yield: N/A
• Average Volume (3M): 4.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.55
• Revenue Growth: -4.90%
• EPS Growth: -69.80%
• Country: DE
• Employees: 296
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 21,847,494
• 10 Day Avg. Volume: 2,853
• 30 Day Avg. Volume: 4,681
• PEG Ratio: -0.58
• Price to Book (P/B): 3.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €6.90
• Price Target Upside: 236.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 43 Neutral
• Price Target: €2.00 ▼(-2.44%Downside)

The stock score reflects significant financial performance challenges, particularly in profitability and cash flow. Weak technical indicators contribute to a negative outlook. Valuation concerns are underscored by a negative P/E ratio, impacting overall attractiveness.

B.R.A.I.N. Biotechnology Research and Information Network Business Overview & Revenue Model

Company Description

B.R.A.I.N. Biotechnology Research and Information Network (BNN) is a prominent player in the biotechnology sector, specializing in the development of innovative solutions that leverage biological processes for industrial applications. The company focuses on creating sustainable alternatives and enhancing processes across various industries, including agriculture, food and nutrition, and health. Its core products and services include enzyme production, microbial strain development, and advanced bioprocess technologies aimed at improving efficiency and sustainability.

How the Company Makes Money

B.R.A.I.N. Biotechnology Research and Information Network (BNN) generates revenue through a diversified model that includes product sales, licensing agreements, and collaborative partnerships. The company's primary revenue stream stems from the sale of proprietary enzymes and microbial strains that are used in various industrial applications. Additionally, BNN engages in strategic partnerships with other firms and research institutions, allowing it to license its technologies and earn royalties. The company also collaborates on research and development projects, which can lead to joint ventures or co-development agreements, further contributing to its revenue. By focusing on innovation and sustainability, BNN positions itself as a leader in the biotechnology industry, which enhances its market appeal and financial performance.

B.R.A.I.N. Biotechnology Research and Information Network Financial Statement Overview

Summary

Financial challenges are evident with net losses and negative cash flows. While there is revenue growth, profitability and liquidity are major concerns. The balance sheet shows some improvement in debt management, yet financial stability remains weak.

Income Statement

The company shows a concerning trajectory with consistent net losses and declining profit margins. The TTM data indicates a negative EBIT and EBITDA, suggesting operational inefficiencies. Revenue has shown some growth over the years, but the net profit margin remains negative, indicating profitability challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, but recent TTM data suggests no total debt, indicating improvement in leverage. The equity ratio is low, reflecting potential risk. Historical stockholders' equity decline suggests financial instability.

Cash Flow

Operating cash flow is negative, indicating difficulties in generating cash from operations. Free cash flow remains negative, though recent financing activities have improved liquidity. The consistent negative free cash flow to net income ratio highlights ongoing cash flow challenges.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
67.74M	54.63M	55.34M	49.51M	38.39M	38.23M
	Gross Profit
23.11M	30.33M	3.47M	27.45M	21.57M	21.20M
	EBIT
-11.92M	-8.85M	-6.71M	-6.89M	-7.83M	-7.99M
	EBITDA
-4.67M	-4.23M	-1.98M	-1.30M	2.01M	-4.92M
	Net Income Common Stockholders
-15.16M	-11.13M	-8.28M	-6.34M	-4.68M	-9.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
0.00	27.29M	5.41M	8.80M	24.65M	19.05M
	Total Assets
80.33M	88.74M	70.94M	77.99M	77.74M	72.15M
	Total Debt
0.00	12.80M	4.66M	3.04M	2.64M	30.60M
	Net Debt
0.00	-14.37M	-693.00K	-5.41M	-21.90M	11.65M
	Total Liabilities
70.02M	74.85M	47.92M	43.74M	35.91M	46.01M
	Stockholders Equity
9.04M	12.62M	21.77M	29.64M	38.78M	20.79M
Cash Flow		Free Cash Flow
-8.65M	-5.31M	-6.86M	-7.57M	-5.17M	-7.63M
	Operating Cash Flow
-6.92M	-3.58M	-4.22M	-1.49M	-3.91M	-4.77M
	Investing Cash Flow
-1.95M	-1.69M	562.00K	-12.69M	-2.18M	-4.47M
	Financing Cash Flow
21.14M	26.99M	459.00K	-1.97M	11.57M	13.09M

B.R.A.I.N. Biotechnology Research and Information Network Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BNN, the sentiment is Negative. The current price of 2.05 is below the 20-day moving average (MA) of 2.08, below the 50-day MA of 2.17, and below the 200-day MA of 2.62, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 40.20 is Neutral, neither overbought nor oversold. The STOCH value of 24.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:BNN.

B.R.A.I.N. Biotechnology Research and Information Network Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HPHA	55 Neutral	€200.85M	―	-59.35%	―	-24.29%	-13.92%
Sector *	54 Neutral	$5.34B	3.36	-45.10%	3.39%	16.81%	-0.03%
BNN	43 Neutral	€45.01M	―	-111.86%	―	-4.90%	-69.80%